Neogenomics Inc risk profile
63 Stretched several inputs deteriorating together
Measured 21 October 2026 from NEO's filed statements. Recomputed nightly.
63 (Stretched), driven by Cash conversion at 87, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 49 | Elevated | Volatile | One-year price volatility — 53.8% |
| Operating pressure | 23 | Normal | Stable | Costs outgrowing revenue — -0.8 percentage points |
| Cash conversion | 87 | Acute | Easing | Capital spending against operating cash — 5.16x |
| Leverage and coverage | 81 | Acute | Easing | Net debt to EBITDA |
| Competitive position | 73 | Stretched | Stable | Operating-margin gap against peers — -19.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.